OTCMKTS:BMXMFBioMerieux Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioMerieux SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $150.75 +3.77 (+2.56 %) (As of 07/7/2020 04:00 PM ET) Add Compare Share Today's Range$149.75Now: $150.75▼$150.7550-Day Range$126.00MA: $136.23▼$146.9852-Week Range$75.70Now: $150.75▼$150.75Volume29 shsAverage Volume608 shsMarket Capitalization$17.84 billionP/E Ratio58.43Dividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesSocial Media bioMérieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test based on biomarkers, as well as services for clinical and industrial laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is based in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for BioMerieux. Previous Next 2.5 Community Rank Outperform VotesBioMerieux has received 98 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioMerieux has received 98 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioMerieux has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BioMerieux and other stocks. Vote “Outperform” if you believe BMXMF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMXMF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioMerieux does not currently pay a dividend.Dividend GrowthBioMerieux does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMerieux insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioMerieux are expected to grow by 12.59% in the coming year, from $2.78 to $3.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMerieux is 58.43, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.72.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMerieux is 58.43, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.30.Price to Book Value per Share RatioBioMerieux has a P/B Ratio of 7.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.63 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BMXMF Previous Symbol CUSIPN/A CIKN/A Webwww.biomerieux.com Phone33-4-78-87-20-00Debt Debt-to-Equity Ratio0.07 Current Ratio1.23 Quick Ratio0.81Price-To-Earnings Trailing P/E Ratio58.43 Forward P/E Ratio54.23 P/E GrowthN/A Sales & Book Value Annual Sales$3.00 billion Price / Sales5.96 Cash FlowN/A Price / Cash FlowN/A Book Value$21.33 per share Price / Book7.07Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees12,000 Outstanding Shares118,361,000Market Cap$17.84 billion Next Earnings DateN/A OptionableNot Optionable OTC:BMXMF Rates by TradingView Receive BMXMF News and Ratings via Email Sign-up to receive the latest news and ratings for BMXMF and its competitors with MarketBeat's FREE daily newsletter. BioMerieux (OTCMKTS:BMXMF) Frequently Asked Questions How has BioMerieux's stock been impacted by COVID-19 (Coronavirus)? BioMerieux's stock was trading at $91.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BMXMF shares have increased by 64.8% and is now trading at $150.75. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of BioMerieux? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMerieux in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for BioMerieux. Has BioMerieux been receiving favorable news coverage? Media stories about BMXMF stock have been trending negative this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BioMerieux earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about BioMerieux. Who are some of BioMerieux's key competitors? Some companies that are related to BioMerieux include Aurora Cannabis (ACBFF), Carillion (CIOIF), Constellation Software (CNSWF), Countrywide (CYWDF), Cybg (CBBYF), Debenhams (DBHSY), Enquest (ENQUF), Hitachi Kokusai Electric (HTKKY), HOPEWELL HOLDIN/ADR (HOWWY), IQE (IQEPF), Loomis (LOIMF), Pax Global Technology (PXGYF), Purplebricks Group (PRPPF), SOCO International (SOCLF) and SSP GROU/PAR VTG FPD 0.01033333 (SSPPF). View all competitors. Who are BioMerieux's key executives? BioMerieux's management team includes the following people: Mr. Alexandre Mérieux, Chairman & CEO (Age 45)Mr. Guillaume Bouhours, Exec. VP and Exec. VP of Fin., Purchasing & Information Systems (Age 43)Sylvain Morgeau, Investor RelationsMs. Valérie Leyldé, Exec. VP of HR and CommunicationsMr. Michel Baguenault, Exec. VP & Company Sec. What is BioMerieux's stock symbol? BioMerieux trades on the OTCMKTS under the ticker symbol "BMXMF." How do I buy shares of BioMerieux? Shares of BMXMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BioMerieux's stock price today? One share of BMXMF stock can currently be purchased for approximately $150.75. How big of a company is BioMerieux? BioMerieux has a market capitalization of $17.84 billion and generates $3.00 billion in revenue each year. The company earns $305.54 million in net income (profit) each year or $2.58 on an earnings per share basis. BioMerieux employs 12,000 workers across the globe. What is BioMerieux's official website? The official website for BioMerieux is www.biomerieux.com. How can I contact BioMerieux? BioMerieux's mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company can be reached via phone at 33-4-78-87-20-00 or via email at [email protected] This page was last updated on 7/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
